How Cell-Free Protein Synthesis Works—and Why It Matters

Making Proteins Without Living Cells

Every drug, diagnostic test, and biological therapy relies on proteins — but producing them has traditionally meant coaxing living cells to do the work. Researchers genetically engineer bacteria or yeast, grow them in bioreactors, and wait days or weeks for results. It is slow, expensive, and limited by the fact that cells have their own survival priorities.

Cell-free protein synthesis (CFPS) upends that model entirely. Instead of keeping cells alive, scientists crack them open, extract their molecular machinery, and use it directly to build proteins in a test tube. The result is a system that can produce functional proteins in as little as a few hours, with a level of control that traditional cell-based methods cannot match.

How the Process Works

At its core, CFPS mimics what happens inside a living cell — but without the cell. The process begins by preparing a cell extract, typically from Escherichia coli, wheat germ, rabbit reticulocytes, or insect cells. These extracts contain ribosomes, enzymes, transfer RNAs, and other components needed to read genetic instructions and assemble proteins.

Scientists then add a DNA template — either a plasmid or a simple PCR product — encoding the target protein. They also supply an energy source (usually ATP and GTP), amino acids, and cofactors. The extract's ribosomes read the DNA's messenger RNA transcript and stitch amino acids together into a finished protein, all in an open reaction vessel.

Because there is no cell membrane enclosing the reaction, researchers can directly manipulate conditions in real time: adjusting pH, temperature, adding chemical labels, or incorporating non-natural amino acids that living cells would reject.

Why It Outperforms Traditional Methods

The advantages of CFPS stem from one fundamental difference: the system has no obligation to keep a cell alive. In conventional cell-based production, much of the cell's energy goes toward growth, DNA replication, and maintenance. In a cell-free system, all resources are channelled toward making the target protein.

This brings several practical benefits:

• Speed — A CFPS reaction can go from gene to protein in two to six hours, compared with days or weeks for cell-based expression.
• Toxic proteins — Some medically important proteins kill the cells that try to make them. Without a living host, toxicity is irrelevant.
• Flexibility — Researchers can produce membrane proteins, virus-like particles, and proteins from genes with unusual codon usage — all notoriously difficult in living cells.
• Portability — Freeze-dried CFPS kits can be stored at room temperature and activated with water, enabling diagnostics and vaccine production in remote settings.

Real-World Applications

The technology is already reshaping several fields. In drug discovery, cell-free platforms now enable ultra-high-throughput screening of peptide libraries, helping researchers identify therapeutic candidates far faster than conventional methods allow. A 2026 study published in Physical Chemistry Chemical Physics demonstrated a cell-free platform capable of screening drug-binding peptides even under harsh chemical conditions that would destroy living cells.

In vaccine development, CFPS has been used to rapidly produce virus-like particles and antigen candidates. During pandemic preparedness exercises, its speed — gene sequence to candidate protein in hours — makes it a powerful first-response tool.

The technology also shows promise for on-demand manufacturing. Because freeze-dried cell-free systems need no refrigeration, organisations including the U.S. Department of Energy have explored them for decentralised production of enzymes, biosensors, and therapeutic proteins in field hospitals or developing regions.

Challenges and Limitations

CFPS is not a universal replacement for cell-based production. Reaction volumes remain relatively small, making industrial-scale manufacturing of commodity proteins — such as insulin — still more practical in bioreactors. The cost of purified energy substrates and amino acid mixtures can also be high, though recent work published in Nature Communications has optimised low-cost reagent formulations that improve both yield and reproducibility.

Post-translational modifications — the chemical tweaks cells add to proteins after assembly, such as glycosylation — remain harder to achieve in cell-free systems, although eukaryotic extracts from insect cells and wheat germ partially address this gap.

The Road Ahead

As synthetic biology advances, cell-free systems are becoming a cornerstone technology. They offer researchers a fast, flexible, and increasingly affordable way to prototype biological designs, screen drug candidates, and manufacture proteins where and when they are needed. For a field long constrained by the pace of living cells, CFPS represents a fundamental shift: biology on demand, no cells required.